HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)
HeartSciences, a medical device company leading innovation in electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today the results of a clinical study serially conducted at The Icahn School of Medicine, Mount Sinai Hospital, New York, NY and the West Virginia University (WVU) Heart and Vascular Institute, Morgantown, WV. The results were provided at onlineJACC.org, April 09, 2018 and will be published in the April 17, 2018 issue of Journal of the American College of Cardiology (JACC), a peer-reviewed journal in cardiovascular medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410005607/en/
HeartSciences’ MyoVista wavECG Device with Informatics (Photo: Business Wire)
The article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presents the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista ® Wavelet ECG (wavECGTM) as a diagnostic tool for predicting myocardial relaxation abnormalities. Abnormal relaxation is an early feature of many types of heart disease and a key characteristic of left ventricular diastolic dysfunction (LVDD). It is typically detected using echocardiographic imaging. LVDD is a strong predictor of cardiovascular and all-cause mortality.1 Ischemia, hypertension, diabetes, valvular disease and reduced systolic function are all associated with LVDD.1, 2
Results from the feasibility study demonstrate MyoVista patented technology can detect myocardial relaxation abnormalities associated with LVDD. The study results demonstrated 80% sensitivity and 84% specificity with an area under the curve of 91% for the prediction of low (e’), an echocardiographic parameter widely used in determination of LVDD. Prediction of low (e’) also correctly identified 23 out of 28 study subjects (82%) with significant underlying coronary artery disease. Additionally, MyoVista wavECG prediction of relaxation abnormalities also allowed recognition of subjects with more advanced stages of DD and concurrent CAD with significantly more incremental value compared with clinical variables and conventional ECG information. The feasibility study was performed using machine learning analysis often described as artificial intelligence or AI. The study included a limited number of patients as well as other limitations and future studies were recommended to address these limitations.
Conclusions of the trial suggest a potential role for the MyoVista wavECG Device as a screening tool for patients at risk for LVDD that would benefit from echocardiographic evaluations.
Partho Sengupta, MD, Professor, Chief of Cardiology and Chair of Cardiac Innovation, WVU Heart & Vascular Institute and Principal Investigator in the study, commented, “These data are extremely encouraging as they suggest a potential role of signal processed ECG in early cardiac disease detection. It is quite remarkable that MyoVista demonstrated a high diagnostic precision in detecting a state of cardiac muscle dysfunction only previously detectable using cardiac ultrasound techniques. This can eventually help in appropriate cardiac testing and reduce overall healthcare costs.”
"These positive results demonstrate that MyoVista wavECG Technology, which includes our patented signal processing methods combined with artificial intelligence, can lead to enhanced capabilities and completely new uses for electrocardiography-based (ECG) devices,” stated Mark Hilz, President and CEO of HeartSciences.
Andrew Simpson, Chairman of HeartSciences, stated, “This study of MyoVista wavelet ECG technology is a significant step towards enhancing the most commonly used low-cost, front-line tool, the 12-lead resting ECG, with new capabilities that can provide more effective risk stratification related to the early detection of heart disease.”
A total of 188 subjects referred from outpatient clinics to the Icahn School of Medicine, Mount Sinai Hospital for coronary computed tomography (CT) angiography also undertook in the same visit, comprehensive two-dimensional echocardiography (including tissue Doppler) that included assessment of LVDD. Subjects with arrhythmias, unstable angina, previous cardiac surgery, a pacemaker, chest deformity, or an inability to express well-defined mitral annular velocities due to severe mitral annular calcifications were excluded. Additional analysis was conducted related to a comparison cohort that were evaluated at WVU, Heart and Vascular Institute which further validated MyoVista wavECG healthy patient characteristics as well as age and population distribution information.
1. LV Diastolic Dysfunction and Prognosis, Dalane W. Kitzman, et al., Circulation, 2012 February 14: 125(6): 743-745. doi:10.1161.CIRCULATIONAHA.111.086843
2. Diastolic Dysfunction and Diastolic Heart Failure: Diagnostic, Prognostic and Therapeutic Aspects, Maurizio Galderisi, Cardiovascular Ultrasound, 2005, 3-9 doi:10.1186/1476-7120-3-9
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Device is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently available for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Manchester United Shoots for Success with a “Digital Experience Platform” Powered by HCL16.8.2018 22:02 | Tiedote
Manchester United (NYSE:MANU) has today announced a major milestone on its digital transformation journey with HCL Technologies, with the successful launch of the Manchester United Official app powered by HCL’s digital experience platform. The launch is part of the ongoing digital transformation of the club to provide a real-time, engaging, personalized, and unified experience to Manchester United’s 659 million global followers, which supports the club’s strategy to become a Digital Sports Enterprise. At the heart of this transformation is the digital platform developed by HCL, providing the club with a single view of fans across web and app touchpoints, offering fans a one-stop shop for everything Manchester United. Manchester United’s Group Managing Director Richard Arnold comments: “This app will allow our 659 million Manchester United followers to easily connect to the club they love, wherever they are in the world. Fans will now have the opportunity to follow all Manchester United
4K 4Charity Fun Run Announces Open Registration for IBC201816.8.2018 20:41 | Tiedote
AWS Elemental, an Amazon Web Services (AWS) company, today announced that the fifth annual 4K 4Charity Fun Run at IBC Show will take place at 7:00 a.m. local time on Saturday, Sept. 15 at Amstelpark in Amsterdam. Registration is open at https://4k4charity.com/ibc. Among the non-profits supported by the 4K 4Charity Fun Run at IBC Show is Amsterdam-based StichtingNewTechKids, which provides computer science education for girls, minorities, and economically challenged youth in the Netherlands. The organization supports a computer science teacher training program for primary school teachers with proceeds from 4K 4Charity. Also supported is Iridescent, a global education non-profit that empowers underrepresented young people to become innovators and leaders through engineering and technology. Through their two programs, Curiosity Machine AI Family Challenge and Technovation, Iridescent introduces underserved communities to new technologies and empowers and equips them to apply those technol
2018 D.I.C.E. Cannes Announced Round 3 Speakers16.8.2018 17:01 | Tiedote
The Academy of Interactive Arts & Sciences’ D.I.C.E. Cannes event will take place 9-11 September 2018 at the Hotel Barrière Le Majestic Cannes in France. Leading video game executives will participate in the premier networking opportunities, listen to key speakers address the conference theme - Trailblazers - to tackle some of the industry’s biggest ideas and trends. Newly announced speakers include: Craig Duncan, Studio Head at Rare – Duncan will share his studio’s experience and learnings with “A Rare Voyage of Adventure.” Duncan will provide insight into Rare’s bold new IP Sea of Thieves, a game that has inspired friendships and players creating stories together. David Hubert, Animation and Cinematic Director at Eidos Montreal – In Hubert’s talk he will discuss how cinematics are redefining AAA story-driven games and how they will continue to shape the medium to push the envelope throughout the production process. Adam Orth – In a session titled “Digging for Fire: Virtual Reality 20
GN Hearing and Google Announce Partnership to Bring Direct Mobile Streaming from Android Devices to Hearing Aids16.8.2018 16:00 | Tiedote
GN Hearing and Google have today announced a new technology partnership that will make GN Hearing the first manufacturer to enable a full spectrum of direct audio streaming from Android devices to hearing aids. The expectations are that direct streaming will become available to hearing aid users of the recently launched hearing aids ReSound LiNX Quattro™ and Beltone Amaze™ in a future Android release. “According to the World Health Organization, around 466 million people worldwide have disabling hearing loss. This number is expected to increase to 900 million people by the year 2050. Google is working with GN Hearing to create a new open specification for hearing aid streaming support on future versions of Android devices,” states Seang Chau, Vice President of Engineering at Google. Users will be able to connect and monitor their hearing aids, so they can get the full advantages of their Android devices without using an intermediate device for streaming to their hearing aids. This will
Zurich Expands Global Use of Guidewire InsurancePlatform with Selection of Guidewire Cyence Risk Analytics16.8.2018 15:55 | Tiedote
Guidewire Software, Inc. (NYSE: GWRE), the provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that Zurich Insurance Group (Zurich) has selected Guidewire Cyence™ Risk Analytics (Cyence) to leverage the cyber risk knowledge and insights the solution provides to help the company prospect, underwrite, and price risks. Zurich will roll out Cyence globally with an emphasis on enhanced analytics and intelligence for risk selection. Unprecedented technological advances of the 21st century have shifted the nature of risk across the P&C insurance industry. Ever-evolving cyber risks present unique challenges including limited availability of traditional actuarial data needed to model these risks. Cyence combines economic modeling, cybersecurity, machine learning and Internet scale data collection to help risk takers assess the financial impact of cyber risk. “After conducting a thorough search, we found that the capabilities of Guidewire Cyence Risk
Scientist.com Named One of America’s Ten Fastest-Growing Private Companies by Inc. Magazine16.8.2018 15:06 | Tiedote
Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it ranked no. 9 on Inc. magazine’s 2018 list of the 5,000 fastest-growing, privately owned companies in America. Scientist.com ranked no. 2 nationally in the Health category and no. 2 in the state of California. The San Diego-based company builds private marketplaces that connect life science research organizations with a global network of over 2,600 contract research organizations (CROs) and providers of scientific services. “Our mission is to empower and connect scientists worldwide and make it possible to cure all human diseases by 2050,” stated Kevin Lustig, Scientist.com’s CEO and Founder. “On Scientist.com, a single, highly trained scientist can run an entire drug discovery program from concept to clinic from his or her laptop without ever physically entering a laboratory.” The pharmaceutical industry spends about $150B a year on medical research and produces about 25 new medic
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme